Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai: Overseas Sales Up 53%, Accounting for 42.9% of Total Sales
June 3, 2002
- Taiho Aims at Sales of \140 Bil. in 2004
June 3, 2002
- Daiichi: Record-high Sales, Profits Thanks to Cravit
June 3, 2002
- BUSINESS NEWS IN BRIEF
June 3, 2002
- Taisho: Sales Down 1.1% due to Slump of OTC Drugs
June 3, 2002
- NEW PRODUCTS
June 3, 2002
- Banyu: Nu-lotan Contributes to Good Sales, Profits
June 3, 2002
- 9 Drugs Including Elaspol to Be Included in NHI List
June 3, 2002
- Sumitomo: Mainstays Drive Sales, Profits
June 3, 2002
- Korosho Listens to Opinions from Industry on Its Proposed Industry Vision
June 3, 2002
- Santen: Overseas Sales Make Up for Poor Domestic Performance
June 3, 2002
- REGULATORY NEWS IN BRIEF
June 3, 2002
- Asahi Kasei: Flivas, Toledomin Prop Up Drug Business
June 3, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 3, 2002
- All Major Listed Wholesalers Report Increases in Sales
June 3, 2002
- PII Results of Iressa Reported at ASCO
June 3, 2002
- We Are in Predawn of Radical Reform: Mr Nagayama of JPMA
June 3, 2002
- New Shionogi Cephem Antibiotic Shows Good Effects on MRSA
June 3, 2002
- Dainippon Licenses Ca Antagonist from Recordati
June 3, 2002
- Panasonic Develops High-throughput Drug Screening Technology
June 3, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…